Amivantamab’s mechanism of action

Amivantamab (Amivantamab) is an innovative bispecific antibody whose mechanism of action is different from traditional monoclonal antibodies. It is designed to bind two different molecular targets simultaneously, thereby achieving multiple biological effects. The mechanism of action of evantumumab mainly involves the following aspects:

1.EGFR (Epidermal Growth Factor Receptor) Inhibition: Part of the structure of evantumumab allows it to bind to EGFR. EGFR is a receptor tyrosine kinase that plays a key role in a variety of malignant tumors. When the EGFR receptor is stimulated by specific signaling molecules, such as epidermal growth factor, it prompts tumor cells to grow and divide. Evantumumabbinds toEGFR and blocks these signals, thereby slowing or stopping the growth of cancer cells.

2.MET (tumor neoantigen) inhibition: Another part of the structure of evantumumab can bind to the MET receptor. MET is a receptor tyrosine kinase that plays an important role in the metastasis and invasion of cancer cells. Evantumumab’s METinhibitory effect helps slow the migration and spread of cancer cells.

3.Bispecific effect: The key innovation is that evantumumab is able to bind EGFR and MET simultaneously. Through this bispecific antibody design, evantumumab can exert effects on two different molecular targets, linking them together. This helps to more effectively inhibit a variety of biological processes, including inhibiting cell growth, curbing invasion and metastasis, and reducing drug resistance.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.